The market status of China's immunomodulatory drug industry.
China's immunomodulatory drug industry is an emerging market with rapid development. The market size of China's immunomodulatory drug industry is increasing, and its market share is also increasing. Number according toMarket Research**Released2023-2029 China Immunomodulatory Drugs Industry Market Supply and Demand Situation and Investment Strategy** ReportAccording to the analysis, in 2018, the operating income of the national immunomodulatory drug industry reached 22 trillion yuan, an increase of 11% year-on-year, and the market share reached 57%。
The development momentum of China's immunomodulatory drug industry is still strong. According to the survey, in 2020, the market share of the national immunomodulatory drug industry will reach 62%, operating income will reach 26 trillion yuan, a year-on-year increase of 10%. From the perspective of industry structure, the market share of China's immunomodulatory drug industry is mainly composed of anti-inflammatory drugs, anti-infective drugs, anti-allergic drugs and anti-tumor drugs, among which anti-inflammatory drugs occupy the largest market share, accounting for 482%。
The competitive landscape of China's immunomodulatory drug industry.
The competitive landscape of China's immunomodulatory drug industry has been initially formed, and in this industry, there are mainly the following competitive patterns:
The competitive landscape of China's immunomodulatory drug industry is that of large enterprises and small enterprises. The main enterprises in China's immunomodulatory drug industry include BGI, Institute of Chemistry of the Chinese Academy of Sciences, iFLYTEK, Crystal Treasure, etc., all of which are large enterprises. And small enterprises mainly include small pharmaceutical companies, small pharmaceutical companies, etc.
The competitive landscape of China's immunomodulatory drug industry is also that of large-scale manufacturers and small-scale manufacturers. In this pattern, large-scale production enterprises are mainly some large state-owned enterprises, such as China Pharmaceutical University, Institute of Materia Medica, Chinese Academy of Sciences, etc., whose product quality and research and development capabilities are better, and the products are also lower. The small-scale production enterprises are mainly some small private enterprises, their product quality and research and development capabilities are generally low, and the products are also high.
The competitive landscape of China's immunomodulatory drug industry is still the competitive landscape between diversified enterprises and single enterprises. In this pattern, diversified enterprises are mainly some large enterprises, such as BGI, Institute of Chemistry of the Chinese Academy of Sciences, etc., which can provide a variety of immunomodulatory drugsMonopolies, on the other hand, are mainly small businesses that can only provide a single type of immunomodulatory drug.
According to the competition pattern of China's immunomodulatory drug industry, there is still a certain imbalance, with small enterprises and small-scale production enterprises still in a disadvantageous position, while large enterprises and large-scale production enterprises occupy a dominant position.